Australia - engleză - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine hydrogen tartrate, quantity: 7.2 mg - capsule - excipient ingredients: iron oxide yellow; stearic acid; microcrystalline cellulose; titanium dioxide; maize starch; iron oxide red; gelatin; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type

Australia - engleză - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine hydrogen tartrate, quantity: 7.2 mg - capsule - excipient ingredients: gelatin; iron oxide yellow; iron oxide red; microcrystalline cellulose; maize starch; titanium dioxide; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - rivastigmine tartrate 4.8mg (rivastigmine hydrogen tartrate equivalent to 3 mg rivastigmine); rivastigmine tartrate 4.8mg (rivastigmine hydrogen tartrate equivalent to 3 mg rivastigmine) - capsule - 3 mg - active: rivastigmine tartrate 4.8mg (rivastigmine hydrogen tartrate equivalent to 3 mg rivastigmine) excipient: colloidal silicon dioxide gelatin hypromellose iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose opacode brown s-1-9460hv purified water sodium laurilsulfate titanium dioxide active: rivastigmine tartrate 4.8mg (rivastigmine hydrogen tartrate equivalent to 3 mg rivastigmine) excipient: colloidal silicon dioxide gelatin hypromellose iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose opacode brown s-1-9460hv opacode red s-1-1666 purified water sodium laurilsulfate titanium dioxide - treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - rivastigmine tartrate 9.6mg (rivastigmine hydrogen tartrate equivalent to 6 mg rivastigmine); rivastigmine tartrate 9.6mg (rivastigmine hydrogen tartrate equivalent to 6 mg rivastigmine) - capsule - 6 mg - active: rivastigmine tartrate 9.6mg (rivastigmine hydrogen tartrate equivalent to 6 mg rivastigmine) excipient: colloidal silicon dioxide gelatin hypromellose iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose opacode brown s-1-9460hv purified water sodium laurilsulfate titanium dioxide active: rivastigmine tartrate 9.6mg (rivastigmine hydrogen tartrate equivalent to 6 mg rivastigmine) excipient: colloidal silicon dioxide gelatin hypromellose iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose opacode brown s-1-9460hv opacode red s-1-1666 purified water sodium laurilsulfate titanium dioxide - treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease.

Regatul Unit - engleză - myHealthbox

rosemont pharmaceuticals ltd - rivastigmine hydrogen tartrate - oral solution - 2mg for ml - psychoanaleptics, anticholinesterases - symptomatic treatment of mild to moderately severe alzheimer's dementia; symptomatic treatment of mild to moderately severe dementia in patients with idiopathic parkinson's disease.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rivastigmine hydrogen tartrate, quantity: 9.6 mg (equivalent: rivastigmine, qty 6 mg) - capsule, hard - excipient ingredients: iron oxide red; magnesium stearate; microcrystalline cellulose; titanium dioxide; colloidal anhydrous silica; iron oxide yellow; gelatin; hypromellose; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; allura red ac; povidone; sodium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rivastigmine hydrogen tartrate, quantity: 7.2 mg (equivalent: rivastigmine, qty 4.5 mg) - capsule, hard - excipient ingredients: sodium lauryl sulfate; titanium dioxide; iron oxide red; magnesium stearate; hypromellose; gelatin; colloidal anhydrous silica; iron oxide yellow; microcrystalline cellulose; propylene glycol; ethanol; isopropyl alcohol; shellac; povidone; tert-butyl alcohol; sodium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rivastigmine hydrogen tartrate, quantity: 4.8 mg (equivalent: rivastigmine, qty 3 mg) - capsule, hard - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; hypromellose; iron oxide yellow; sodium lauryl sulfate; sunset yellow fcf; magnesium stearate; gelatin; brilliant scarlet 4r; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; allura red ac; povidone; sodium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rivastigmine hydrogen tartrate, quantity: 2.4 mg (equivalent: rivastigmine, qty 1.5 mg) - capsule, hard - excipient ingredients: sunset yellow fcf; titanium dioxide; microcrystalline cellulose; iron oxide yellow; sodium lauryl sulfate; gelatin; hypromellose; magnesium stearate; colloidal anhydrous silica; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; allura red ac; povidone; sodium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - rivastigmine hydrogen tartrate, quantity: 3.2 mg/ml (equivalent: rivastigmine, qty 2 mg/ml) - oral liquid, solution - excipient ingredients: citric acid; sodium citrate dihydrate; purified water; sodium benzoate; quinoline yellow - exelon is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type.